We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Nestle SA (PK) | USOTC:NSRGY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.14 | -1.03% | 109.17 | 108.54 | 110.15 | 109.68 | 108.94 | 109.48 | 360,613 | 21:17:25 |
From Jun 2022 to Jun 2024
--Nestle SA has started a process to sell its peanut-allergy treatment Palforzia, Bloomberg reports, citing unnamed sources.
--Initial bids are expected next month, but no final decision has been made on the timing of any sale, Bloomberg reports.
--Nestle, which bought the maker of Palforzia in a $2.6 billion deal in 2020 and recently announced a $2.1 billion impairment charge on the medication, declined to comment.
Full story: https://bloom.bg/3y2fmuv
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
March 02, 2023 03:27 ET (08:27 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Nestle (PK) Chart |
1 Month Nestle (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
